Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,381 to 2,400 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Standard Practice vs Personal Hand Hygiene Device: deaths from any cause | 6 of 1,620 7 of 1,636 | -0.1 points -0.6 to 0.4 | 3,256 | NCT02252562 Hand Hygiene and Hospital Acquired Infections |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause | 48 of 1,622 61 of 1,628 | -0.8 points -2.0 to 0.5 | 3,250 | NCT01275677 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events | 31 of 1,615 96 of 1,625 | -4.0 points -5.4 to -2.7 | 3,240 | NCT01275677 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer |
| Clodronate vs Placebo: deaths from any cause | 5 of 1,612 12 of 1,623 | -0.4 points -1.0 to 0.1 | 3,235 | NCT00009945 Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer |
| Clodronate vs Placebo: serious adverse events | 340 of 1,612 350 of 1,623 | -0.5 points -3.3 to 2.4 | 3,235 | NCT00009945 Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: 12-month Composite Major Adverse Cardiac Event (MACE) | 421 of 2,439 140 of 787 | -0.5 points -3.7 to 2.4 | 3,226 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 2 | 1,487 of 1,614 1,486 of 1,610 | -0.2 points -2.0 to 1.7 | 3,224 | NCT03164564 Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
| Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: Number of Pariicipants With Documented Incident HIV Infections | 4 of 1,614 36 of 1,610 | -2.0 points -2.8 to -1.3 | 3,224 | NCT03164564 Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
| Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: deaths from any cause | 3 of 1,614 0 of 1,610 | 0.2 points -0.1 to 0.5 | 3,224 | NCT03164564 Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
| Arm A: CAB + Placebo TDF/FTC + CAB LA vs Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA: serious adverse events | 33 of 1,614 33 of 1,610 | -0.0 points -1.0 to 1.0 | 3,224 | NCT03164564 Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
| Dronedarone vs Placebo: serious adverse events | 113 of 1,614 77 of 1,609 | 2.2 points 0.6 to 3.9 | 3,223 | NCT01151137 Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy |
| qHPV in Base Study vs Placebo in Base Study: Number of Participants With Vaccine-Related SAEs After Vaccine Administration | 0 of 1,890 1 of 1,327 | -0.1 points -0.4 to 0.1 | 3,217 | NCT00090220 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) |
| qHPV in Base Study: All Participants vs Base Study: Placebo: Number of Participants With an SAE Resulting in Death After Vaccine Administration | 8 of 1,890 4 of 1,327 | 0.1 points -0.4 to 0.6 | 3,217 | NCT00090220 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: All Cause Mortality at 12 Months | 56 of 2,424 19 of 785 | -0.1 points -1.5 to 1.0 | 3,209 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Do-not-resuscitate Order | 1,336 of 1,519 1,504 of 1,687 | -1.2 points -3.4 to 1.0 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Palliative Care Consult Order | 1,208 of 1,519 1,426 of 1,687 | -5.0 points -7.7 to -2.3 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Intravenous Line | 141 of 1,519 184 of 1,687 | -1.6 points -3.7 to 0.5 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Nasogastric Tube | 161 of 1,519 141 of 1,687 | 2.2 points 0.2 to 4.3 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Basic Implementation Approach vs Enhanced Implementation Approach: Location of Death | 436 of 1,519 408 of 1,687 | 4.5 points 1.5 to 7.6 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of a Pastoral Care Visit | 1,060 of 1,519 1,271 of 1,687 | -5.6 points -8.6 to -2.5 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
Code
curl "https://conductscience.org/api/comparisons/v1?page=120"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=120
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02252562-deaths",
"title": "Standard Practice vs Personal Hand Hygiene Device: deaths from any cause",
"summary": "6 of 1620 against 7 of 1636; risk difference -0.1 points, 95% interval -0.6 to 0.4; NCT02252562, Hand Hygiene and Hospital Acquired Infections",
"record": "/library/comparisons/NCT02252562-deaths",
"nct_id": "NCT02252562",
"kind": "deaths",
"participants": 3256,
"risk_difference": {
"value": -0.0005750249026532641,
"lower": -0.005526341145047975,
"upper": 0.004304692530978662
},
"group_1": "6 of 1,620",
"group_2": "7 of 1,636",
"difference": "-0.1 points",
"interval": "-0.6 to 0.4",
"trial_title": "Hand Hygiene and Hospital Acquired Infections"
},
{
"id": "NCT01275677-deaths",
"title": "Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause",
"summary": "48 of 1622 against 61 of 1628; risk difference -0.8 points, 95% interval -2.0 to 0.5; NCT01275677, Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer",
"record": "/library/comparisons/NCT01275677-deaths",
"nct_id": "NCT01275677",
"kind": "deaths",
"participants": 3250,
"risk_difference": {
"value": -0.00787619252477452,
"lower": -0.02049847589553446,
"upper": 0.004608420228512126
},
"group_1": "48 of 1,622",
"group_2": "61 of 1,628",
"difference": "-0.8 points",
"interval": "-2.0 to 0.5",
"trial_title": "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=121",
"request_id": "dG4gvF57MQwxtQ2w"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant